Skip to main content
Clinical Trials/NCT04970472
NCT04970472
Recruiting
Not Applicable

Bio Clinical Collection of Urothelial Carcinoma

University Hospital, Toulouse1 site in 1 country1,000 target enrollmentNovember 16, 2021

Overview

Phase
Not Applicable
Intervention
collection of blood, urines, stool and tumor samples
Conditions
Urothelial Carcinoma
Sponsor
University Hospital, Toulouse
Enrollment
1000
Locations
1
Primary Endpoint
Collection and long-term collection of blood, urines, stool and tumor samples from patients with Urothelial bladder carcinoma for future biological and/or surrogate marker studies.
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this study is to collect tumor samples, urines, stool and blood from patients with urothelial carcinoma. These samples will be stored in a secure and confidential laboratory of the Toulouse University Hospital.

Detailed Description

Recent studies have shown that the bladder also harbors friendly bacteria that are collectively called the microbiome. While the effect of the bladder microbiome to health remains to be more clearly understood, an imbalance in the microbiome is associated with several urinary diseases including overactive bladder and bladder cancer. But whether the microbiome affects the outcome of Bacille Calmette et Guérin (BCG)-immunotherapy or chemotherapy in bladder cancer is still not known. Researchers at Toulouse University Hospital want to learn as much as possible about bladder cancer. One way to do so is by studying what is in your urines, blood, stool, saliva and in your tumor. Patients, who will be agree to take part in this study, will have at least about one tablespoon of blood (as a residual of current biological analysis), 1 container of urines, stool and saliva collected before bladder resection. After transurethral bladder resection or radical cystectomy scheduled as part of the standard of care, some tumor samples might be collected either as fresh tissue or as paraffin embedded tissue and store in a secure and confidential laboratory at Toulouse University Hospital. The patient's follow up will be schedule as the standard of care and no additional visit will be required for the study. Oncological outcome of each patient will be recorded up to 5 years This is an investigational study in which up to 500 patients will take part in the collection. All patients will be all enrolled at Toulouse University Hospital.

Registry
clinicaltrials.gov
Start Date
November 16, 2021
End Date
July 14, 2031
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult \>18 years old
  • Patient with suspected or diagnosed Urothelial carcinoma
  • Patients who are willing to consent for this protocol.

Exclusion Criteria

  • Pregnant or breastfeeding patients
  • Patients under 18 years old
  • Patients under guardianship or curators
  • Patients unable to sign a free and informed consent

Arms & Interventions

patients with Urothelial bladder carcinoma

collection of blood, urines, stool and tumor samples

Intervention: collection of blood, urines, stool and tumor samples

Outcomes

Primary Outcomes

Collection and long-term collection of blood, urines, stool and tumor samples from patients with Urothelial bladder carcinoma for future biological and/or surrogate marker studies.

Time Frame: during the intervention/procedure/surgery

Transcriptomic, proteomic and epigenetic analysis

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Not Applicable
Sample Collection From Melanoma PatientsMelanoma
NCT00507325M.D. Anderson Cancer Center131
Completed
Not Applicable
Collecting Tumor Samples From Patients With Gynecological TumorsBorderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedChildhood Embryonal RhabdomyosarcomaChildhood Malignant Ovarian Germ Cell TumorEndometrioid Stromal SarcomaGestational Trophoblastic TumorMalignant MesotheliomaMalignant Ovarian Epithelial TumorMelanomaNeoplasm of Uncertain Malignant PotentialOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Serous CystadenocarcinomaPaget Disease of the VulvaRecurrent Cervical CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage I Ovarian CancerStage I Uterine Corpus CancerStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IA Ovarian Germ Cell TumorStage IB Cervical CancerStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IB Ovarian Germ Cell TumorStage IC Fallopian Tube CancerStage IC Ovarian CancerStage IC Ovarian Germ Cell TumorStage II Ovarian CancerStage II Uterine Corpus CancerStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIA Ovarian Germ Cell TumorStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian CancerStage IIB Ovarian Germ Cell TumorStage IIC Fallopian Tube CancerStage IIC Ovarian CancerStage IIC Ovarian Germ Cell TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage III Cervical CancerStage III Uterine Corpus CancerStage III Vaginal CancerStage III Vulvar CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal CancerStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerStage IV Uterine Corpus CancerStage IVA Cervical CancerStage IVA Vaginal CancerStage IVB Cervical CancerStage IVB Vaginal CancerStage IVB Vulvar CancerUterine Corpus CancerUterine Corpus LeiomyosarcomaVulvar Squamous Cell Carcinoma
NCT00897442Gynecologic Oncology Group275
Completed
Not Applicable
Urine Cytology and Utility in Bladder RecurrenceBladder Cancer
NCT00971256William Beaumont Hospitals10
Completed
Not Applicable
Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy ProcedureBladder Disease
NCT00615043Tengion6
Recruiting
Not Applicable
Bladder Bank (a Prospective Banking Study)
NCT06109857Mayo Clinic1,500